Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Angocin Anti-Infekt N
- Development stage
- Phase 4
- Lead developer
- Repha
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Angocin Anti-Infekt N is an approved herbal medicine developed and manufactured by Repha GmbH Biologische Arzneimittel in Germany. The product is a combination of nasturtium herb (*Tropaeoli majoris herba*) and horseradish root (*Armoraciae rusticanae radix*). Its therapeutic mechanism is based on mustard oils (isothiocyanates), which are released through the enzymatic degradation of plant-derived glucosinolates. These isothiocyanates possess broad-spectrum antibacterial, antiviral, and anti-inflammatory properties. Angocin Anti-Infekt N is indicated for the treatment of acute inflammatory diseases of the respiratory tract, such as bronchitis and sinusitis, as well as urinary tract infections like cystitis. It has been licensed in Germany for over 50 years as a non-prescription film-coated tablet and is suitable for adults and children from 6 years of age. Additionally, the active mustard oils are being explored in preclinical research for potential applications in prostate carcinoma.
- Brand names
- Angocin Anti-Infekt NANGOCIN
- Other names
- ANGOCIN Anti-Infekt N
Beyond the preview
Go deeper on Angocin Anti-Infekt N.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Angocin Anti-Infekt N.